Octavio Espinoza, Chief Financial Officer at Ligand Pharmaceuticals, sold LGND on Aug 12, 2026
Data as of Oct 16
▼ SELL$9.2M31,641 shares at $292.06Octavio Espinoza Chief Financial OfficerLGND Ligand Pharmaceuticals Inc
- Traded
- Aug 12, 2026
- Disclosed
- Aug 14, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
LGND since disclosure
+0.3%
after the sale
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund
Change in closing price from Aug 14, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.